Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

36 results about "Phosphoserine" patented technology

Phosphoserine (abbreviated as SEP or J) is an ester of serine and phosphoric acid. Phosphoserine is a component of many proteins as the result of posttranslational modifications. The phosphorylation of the alcohol functional group in serine to produce phosphoserine is catalyzed by various types of kinases. Through the use of technologies that utilize an expanded genetic code, phosphoserine can also be incorporated into proteins during translation.

Bone bonding material with high strength and low immunoreaction as well as preparation method and application method of bone bonding material

The invention discloses a high-strength low-immunoreaction bone bonding material and a preparation and application method thereof. The bone binding material comprises tetracalcium phosphate, serine phosphate, magnesium phosphate and a sodium citrate solution. According to the preparation method, tetracalcium phosphate, phosphoserine, magnesium phosphate powder and a sodium citrate solution are fully mixed and reacted by utilizing a hedging device consisting of a screw injector and a connecting pipe. And extruding the mixed liquid material through a filter membrane to complete the preparation of the bone adhesive material. The bone binding material can be used for preparing bionic sclerotin, binding broken bones in comminuted fractures or smearing the bone binding material to bone gaps, and in the decomposition process, the bone binding material can continuously release magnesium ions, so that the immune environment of early bone repair is regulated and controlled, the bone repair process is accelerated, and bone healing is promoted. Meanwhile, experimental data prove that the bone adhesive material provided by the invention can provide stable supporting strength, has no potential toxicity to fibroblasts, and is good in biocompatibility.
Owner:HANGZHOU ORIGO BIOTECHNOLOGY CO LTD

Milk-derived phosphorylated peptide capable of improving intestinal iron absorption activity and application of milk-derived phosphorylated peptide in preparation of iron supplement

ActiveCN119039415Ahigh activityIncrease iron transport capacityNervous disorderMetabolism disorderIron ChelatingIron supplement
The invention relates to a milk-derived phosphorylated peptide capable of improving intestinal iron absorption activity and application of the milk-derived phosphorylated peptide in preparation of an iron supplement. The sequence of the milk-derived phosphorylated peptide is EESITRINKKIE, and glutamic acid at the amino terminal of the sequence is connected with 1-3 phosphoserine. The milk-derived phosphorylated peptide can be specifically combined with Fe < 2 + >, is high in iron chelating capacity, and can remarkably improve the iron transport amount in a Caco-2 small intestine epithelial cell model, so that the milk-derived phosphorylated peptide has good activity of improving intestinal tract iron absorption, and can be widely applied to the fields of medicines, health-care products or foods.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

O-phosphoserine-producing microorganism and method for producing O-phosphoserine or L-cysteine ​​using the same

The present application relates to a microorganism having weakened erythronate-4-phosphate dehydrogenase protein activity; a method for producing O-phosphoserine, cysteine ​​and cysteine ​​derivatives using the same; a composition for producing O-phosphoserine containing the microorganism; and use of the microorganism for producing O-phosphoserine, cysteine ​​and cysteine ​​derivatives.
Owner:CJ CHEILJEDANG CORP

O-phosphoserine export protein variant and method for producing O-phosphoserine, cysteine, and derivatives thereof using the same

An O-phosphoserine (OPS) export protein variant with increased O-phosphoserine exporting activity, and a method for producing O-phosphoserine, cysteine, and cysteine derivatives using the same. Also provided herein are O-phosphoserine-producing microorganisms, a polynucleotide encoding the O-phosphoserine export protein variant, and a vector containing the polynucleotide encoding the O-phosphoserine export protein variant.
Owner:CJ CHEILJEDANG CORP

A milk-derived phosphorylated peptide with the activity of promoting intestinal iron absorption and its application in the preparation of an iron supplement

The present application relates to a milk-derived phosphorylated peptide with the activity of improving intestinal iron absorption and its application in the preparation of iron supplements. The sequence of the milk-derived phosphorylated peptide is EESITRINKKIE, and the glutamic acid at the amino terminal of the sequence is connected with 1-3 phosphoserines. The milk-derived phosphorylated peptide can be combined with Fe 2+ Specifically bound, strong iron chelating ability, and can significantly improve the iron transport amount in the Caco-2 small intestinal epithelial cell model, thereby having good activity of improving intestinal iron absorption, and can be widely applied in the fields of drugs, health care products or food.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

A bone adhesive-fixed cartilage graft, its preparation method and application

PendingCN123059197ASurgical adhesivesCoatingsBiomimetic coatingBone implant
This invention discloses a cartilage graft fixed with bone adhesive, its preparation method, and its application, belonging to the field of medical repair material preparation technology. The cartilage graft includes a bone implant base coated with a biomimetic coating, a cartilage replacement layer bonded to the base through a gradient mineralization transition layer, and bone adhesive filling the pores of the base. The biomimetic coating contains an adhesive molecule and a complex of phosphoserine, recombinant collagen, and collagen. Bacterial cellulose nanofibers are dispersed in the cartilage replacement layer. This invention achieves immediate intraoperative fixation through pre-placed bone adhesive and utilizes a biomimetic coating and ion pre-activation technology to induce in-situ gradient mineralization of the soft-hard interface, achieving strong integration between the cartilage layer and the bone base. It can be used for the repair of articular cartilage defects and has broad application prospects.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY

Platform for bio-based production of high levels of o-phosphoserine, cysteate, or taurine

Methods for the fermentative production of O-phosphoserine, cysteate, or taurine in microbes or unicellular organisms that contain a serB mutation that either decreases serB expression, reduces the amount of the serB gene product or results in a serB gene product with low enzymatic activity. Genetic modifications of the O-phosphoserine, cysteate, or taurine and / or substrate biosynthetic pathways in unicellular organisms that include bacteria, algae, microalgae, diatoms, yeast, or fungi are disclosed. Also disclosed are fermentation and processing methods for the production of various O-phosphoserine-, cysteate-, or taurine-containing products and the use of the cells, fermentation broth or extracts that contain O-phosphoserine, cysteate, or taurine to produce products for use in food, feed, beverages, dietary and health supplements, cosmetics, personal care, pharmaceuticals, agricultural production, or surfactants.
Owner:NATAUR LLC

Phosphoserine containing compositions for immune tolerance induction

Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.
Owner:THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK

Platform for BIO-based production of high levels of o-phosphoserine, cysteate or taurine

Methods for the fermentative production of O-phosphoserine, cysteate, or taurine in microbes or unicellular organisms that contain a serB mutation that either decreases serB expression, reduces the amount of the serB gene product or results in a serB gene product with low enzymatic activity. Genetic modifications of the O-phosphoserine, cysteate, or taurine and / or substrate biosynthetic pathways in unicellular organisms that include bacteria, algae, microalgae, diatoms, yeast, or fungi are disclosed. Also disclosed are fermentation and processing methods for the production of various O-phosphoserine-, cysteate-, or taurine-containing products and the use of the cells, fermentation broth or extracts that contain O-phosphoserine, cysteate, or taurine to produce products for use in food, feed, beverages, dietary and health supplements, cosmetics, personal care, pharmaceuticals, agricultural production, or surfactants.
Owner:NATAUR LLC

Substances for treatment of hyperuricaemia

A composition for use in a therapeutic method of treatment or prevention of hyperuricaemia, gout and / or renal impairment, said composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and / or phosphoserine; B) N-acetyl cysteine, cysteine and / or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and / or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and / or nicotinate.
Owner:SCANDIBIO THERAPEUTICS AB

Autonomous organisms for synthesis of permanently phosphorylated proteins

Embodiments of the present disclosure provide compositions and methods for biosynthesizing a stable, functional mimic of phosphoserine. The compositions and methods described herein genetically program a host cell to express a biosynthetic pathway that can synthesize the amino acid, 2-amino-4-phosphobobutyric acid, that is a non-hydrolyzable phosphoserine (nhpSer) because it contains a carbon-phosphorus, e.g., phosphonate, bond. In one embodiment the genetically programed cells express the enzymes of a pathway from a Streptomyces bacterium. In some embodiments, nhpSer is translationally incorporated into protein of interest at one or more programmed UAG amber codons using Genetic Code Expansion (GCE) technology.
Owner:THE STATE OF OREGON ACTING BY & THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIV

An anti-fouling electrochemical serum sensor based on phosphoric acid group modified polypeptide, preparation method and application

PendingCN122651832AO-Phosphoric AcidPhytic acid
The application discloses an anti-pollution electrochemical serum sensor based on a phosphoric acid group modified polypeptide, a preparation method and application, and belongs to the technical field of electrochemical detection. A phosphoric acid group is introduced into a polyhydroxy proline polypeptide sequence. The polyhydroxy proline region of the polypeptide has excellent hydrophilicity, can form a hydration layer, and inhibits the adsorption of pollutants through steric hindrance and energy barrier; the terminal contains two phosphoserine branches, and the phosphoric acid group can be stably connected with phytic acid molecules on the substrate through the bridging action of vanadium ions. The sensing interface constructed by the ion coordination method is not affected by biological thiols, and the strong hydrophilicity of phytic acid and the polypeptide endows the interface with excellent anti-pollution ability. The precise detection of three biomarkers (CA15-3, CEA and AFP) can be realized in serum. The comprehensive analysis of the three markers combined with machine learning evaluation can improve the accuracy of early diagnosis of breast cancer.
Owner:QINGDAO UNIV OF SCI & TECH

Multi-enzyme cascade catalytic reaction system and application thereof

PendingCN122168699ATransferasesFermentationSerine aminotransferasePhosphoserine transaminase
This invention provides a multi-enzyme cascade catalytic reaction system and its application, belonging to the field of enzyme catalysis production technology. Using glycerol as a raw material, it includes a first module, a second module, and a third module. The first module involves the production of glyceric acid from glycerol under the catalysis of alditol oxidase. The second module contains glyceric acid, ATP, and NAD+. + L-glutamic acid is synthesized into phosphoserine via glycerate kinase, D-3-phosphoglycerate dehydrogenase, and phosphoserine transaminase. The third module involves phosphoserine and nucleophiles being catalyzed by phosphoserine thioylase to synthesize L-cysteine ​​or a non-natural L-α-amino acid. The multi-enzyme cascade catalytic reaction system provided by this invention can catalyze a variety of nucleophiles, yields high products, is low in cost, causes minimal environmental pollution, and is easily industrialized.
Owner:EAST CHINA UNIV OF SCI & TECH

O-phosphoserine sulfhydrase variant and method for producing cysteine ​​using the same

PendingJP2026522827ACell biologyPhosphoserine
This application relates to an O-phosphoserine sulfhydrase mutant and a method for producing cysteine ​​using the same.
Owner:CJ CHEILJEDANG CORP

Microorganism and method for the improved production of cysteine and / or derivatives thereof

The present invention relates to a microorganism genetically modified for the production of cysteine and / or derivatives thereof, wherein said microorganism comprises the expression of at least one heterologous gene coding an O-phosphoserine sulfhydrylase (OPSS) having a turnover number (kcat) equal or superior to 40 s-1. The present invention also relates to a method for the production of cysteine and / or derivatives thereof using said microorganism.
Owner:METABOLIC EXPLORER

Novel mdth variant and method for producing o-phosphoserine, cysteine, and derivate thereof using same

To provide a method to overproduce its precursor, O-phosphoserine, in order to produce high yield of cysteine.SOLUTION: The present application relates to a novel MdtH variant and a method for producing O-phosphoserine, cysteine, and a derivative of cysteine using the same.SELECTED DRAWING: None
Owner:CJ CHEILJEDANG CORP

Bioadhesive composition

The present invention relates to a two-component composition comprising a first component A comprising water or an aqueous solution, and a second component B comprising: a self-curing adhesive powder comprising at least a polyvalent metal salt and phosphoserine, and at least one mono-carbonate selected from the group consisting of sodium carbonate, ammonium carbonate and potassium carbonate, characterised in that the mono-carbonate is present in a concentration of from 4% to 12% by weight of component B.
Owner:INSTITUT STRAUMANN AG +1

O-phosphoserine sulfhydrylase variant and method for producing cysteine using same

PCT designated stage expiredWO2024248498A1TransferasesFermentationOrganic chemistryPhosphoserine
The present invention relates to an O-phosphoserine sulfhydrylase variant and a method for producing cysteine using same.
Owner:CJ CHEILJEDANG CORP

Bioadhesive composition

A two-component composition including a first component A including water or an aqueous solution, and a second component B including a self-setting adhesive powder including at least a multivalent metal salt and phosphoserine, and at least one monocarbonate selected from the group of sodium carbonate, ammonium carbonate and potassium carbonate, wherein the monocarbonate is present in a concentration between 4 and 12% by weight of component B.
Owner:INSTITUT STRAUMANN AG +1